 Credit Suisse downgraded Immunovant Inc NASDAQ:IMVT to Underperform from Neutral and lowered the price target to 7 from 12. Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months. 